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Epithelial-mesenchymal (EMT) and mesenchymal-epithe-
lial (MET) transitions occur in the development of human
tumorigenesis and are part of the natural history of the
process to adapt to the changing microenvironment. In
this setting, the miR-200 family is recognized as a master
regulator of the epithelial phenotype by targeting ZEB1
and ZEB2, two important transcriptional repressors of the
cell adherence (E-cadherin) and polarity (CRB3 and
LGL2) genes. Recently, the putative DNA methylation
associated inactivation of various miR-200 members has
been described in cancer. Herein, we show that the miR-
200ba429 and miR-200c141 transcripts undergo a dy-
namic epigenetic regulation linked to EMT or MET
phenotypes in tumor progression. The 50-CpG islands of
both miR-200 loci were found unmethylated and coupled
to the expression of the corresponding miRNAs in human
cancer cell lines with epithelial features, such as low levels
of ZEB1/ZEB2 and high expression of E-cadherin, CRB3
and LGL2, while CpG island hypermethylation-associated
silencing was observed in transformed cells with mesench-
ymal characteristics. The recovery of miR-200ba429 and
miR-200c141 expression by stable transfection in the
hypermethylated cells restored the epithelial markers and
inhibited migration in cell culture and tumoral growth and
metastasis formation in nude mice. We also discovered,
using both cell culture and animal models, that the miR-
200 epigenetic silencing is not an static and ﬁxed process
but it can be shifted to hypermethylated or unmethylated
50-CpG island status corresponding to the EMT and MET
phenotypes, respectively. In fact, careful laser microdis-
section in human primary colorectal tumorigenesis
unveiled that in normal colon mucosa crypts (epithelia)
and stroma (mesenchyma) already are unmethylated and
methylated at these loci, respectively; and that the
colorectal tumors undergo selective miR-200 hypermethy-
lation of their epithelial component. These ﬁndings
indicate that the epigenetic silencing plasticity of the
miR-200 family contributes to the evolving and adapting
phenotypes of human tumors.
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Introduction
About 85% of human tumors are derived from
epithelial cells (Edwards et al., 2010). The epithelial-
mesenchymal transition (EMT) involves molecular
reprogramming of the cells that gradually lose their
epithelial features while acquiring mesenchymal attri-
butes that promote cellular detachment from the
primary tumor, invasion of adjacent stroma, entry into
the systemic circulation and extravasation (Thiery, 2002;
Yang and Weinberg, 2008; Acloque et al., 2009; Kalluri
and Weinberg, 2009; Polyak and Weinberg, 2009;
Thiery et al., 2009; Zeisberg and Neilson, 2009). This
might be a reversible process and the cancer cells could
eventually undergo mesenchymal-epithelial transition
(MET) phenotype, then proliferate and form distant
secondary tumors (Brabletz et al., 2001; Chaffer et al.,
2006; Chaffer et al., 2007; Hugo et al., 2007; Polyak and
Weinberg, 2009; Thiery et al., 2009; Aokage et al., 2010).
Thus, epithelial and mesenchymal transitions are
considered to be hallmarks of tumor progression and
also have a central role in metastasis development, the
leading cause of cancer-associated mortality.
From a molecular standpoint, most signaling path-
ways that regulate EMT converge on the control of
E-cadherin, a cell adhesion protein crucial for main-
taining epithelial structure (Peinado et al., 2007). Thus,
the accurate regulation of transcriptional repressors
of this gene, such as ZEB1 (TCF8/ZFHX1A), ZEB2
(SIP1/ZFHX1B), Snail (SNAI1), Slug (SNAI2) and
other factors is crucial for normal epithelium and its
dysregulation in cancer is associated with EMT
(Peinado et al., 2007). In addition, lack of epithelial
organization involves disruption of cell polarity
(Etienne-Manneville, 2008; Moreno-Bueno et al., 2008;
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2010). The E-cadherin repressor ZEB1 also represses the
transcription of some polarity genes, including CRB3
(Crumbs3), MPP5 (Pals1), INADL (Patj) and LLGL2
(Lgl2) (Aigner et al., 2007; Spaderna et al., 2008).
If ZEB1 and ZEB2 have a central role in EMT, their
activity must be ﬁnely regulated. MicroRNAs (miR-
NAs) are small non-coding RNAs that regulate gene
expression by targeting messenger RNA (mRNA)
transcripts (Medina and Slack, 2008; Agami, 2010). It
is at this level that a miRNA family, miR-200, has
important EMT regulatory activity in which it directly
targets and inhibits ZEB1 and ZEB2 (Hurteau et al.,
2006; Christoffersen et al., 2007; Hurteau et al., 2007;
Burk et al., 2008; Gregory et al., 2008; Korpal et al.,
2008; Park et al., 2008). Although several mechanisms
may help control miR-200 activity, such as the existence
of a double-negative feedback loop between the miR-
200 family and ZEB factors based on the presence of E-
boxes in miR-200 genes (Bracken et al., 2008; Burk et al.,
2008), we focused on a common disruption in cancer
cells: the epigenetic inactivation by CpG island hyper-
methylation surrounding the transcription start sites
(Jones and Baylin, 2007; Esteller, 2008). Promoter
hypermethylation and associated silencing of classical
tumor suppressor genes is a molecular hallmark of
human tumors (Jones and Baylin, 2007; Esteller, 2008),
and this epigenetic lesion has recently been extended to
the DNA methylation-associated silencing of miRNAs
with growth-inhibitory features (Saito et al., 2006;
Lujambio et al., 2007; Lujambio et al., 2008; Toyota
et al., 2008; Huang et al., 2009). In this regard, recent
reports have suggested the presence of hypermethyla-
tion-associated silencing of some miR-200 family
members (Ceppi et al., 2010; Neves et al., 2010; Vrba
et al., 2010; Wiklund et al., 2010).
The reversibility of epigenetic mechanisms might be a
strategy for modulating sequences with distinct expres-
sion patterns during tumor progression. This might
occur with miR-200 in association with acquiring initial
mesenchymal attributes (EMT) and, once the cancer
cells have reached a secondary site, regaining some
epithelial properties (MET) for colonization and estab-
lishment of a secondary tumor. Herein, we show that the
50-CpG island hypermethylation-associated silencing of
the miR-200b/200a/429 and miR-200c/141 polycistronic
transcripts is a dynamic process that mediates the shifts
between EMT and MET phenotypes and contributes to
cancer progression and metastasis formation in human
tumorigenesis.
Results
CpG island hypermethylation-associated silencing of the
miR-200 family in cancer cells
In order to evaluate the possible epigenetic regulation of
the miR-200 family by CpG island methylation in
transformed cells, we ﬁrst screened a panel of cancer cell
lines representing the most common human tumor
types: colon (RKO and HCT116), lung (H157, EBC1
and H441) and breast (MDAMB231 and MCF7).
Genetically, the miR-200 family is grouped in two
polycistronic units: miR-200b/200a/429 (200ba429) and
miR-200c/141 (200c141), clustered in chromosomes 1
and 12, respectively (Figure 1a). The miR-200b/200a/
429 and miR-200c/141 transcription start sites have been
previously determined (Bracken et al., 2008; Neves et al.,
2010) and are located within canonical CpG islands
(Figure 1a). The CpG islands of both clusters were
densely methylated in RKO, H157 and MDAMB231,
whereas HCT116, H441, EBC1 and MCF7 were found
to be unmethylated (Figure 1b). Methylation-speciﬁc
PCR analyses conﬁrmed the bisulﬁte genomic sequen-
cing data (Supplementary Figure 1).
To evaluate the impact of CpG methylation in
transcription, we analyzed the expression of miR-200
family members. We observed that all the hypermethy-
lated cancer cell lines had signiﬁcant loss of both mature
(Figure 1c) and pri-miRNA (Supplementary Figure 1)
expression for the miR-200 family relative to the CpG
island unmethylated cell lines derived from the same
tumor type. Treatment of the miR-200 family hyper-
methylated cancer cell lines with the DNA-demethylat-
ing agent 50-aza-20-deoxycytidine restored the expression
of the miRNAs at the mature (Figure 1d) and
pri-miRNA (Supplementary Figure 1) stages.
Epigenetic silencing of the miR-200 family is associated
with upregulation of ZEB1/ZEB2 and downregulation
of their cell-adhesion and polarity-target genes
We next wondered about the impact of miR-200
epigenetic silencing on the expression of ZEB1 and
ZEB2 and on the downstream cell-adhesion and
polarity-target genes, such as E-cadherin (CDH1),
CRB3 and LGL2. We observed that miR-200 family
CpG island hypermethylated cancer cell lines had higher
levels of expression of ZEB1 and ZEB2, quantiﬁed by
qRT–PCR, than did unmethylated cells, in which these
transcripts were inhibited (Supplementary Figure 2).
To reinforce the results of the analysis of the
consequences of miR-200 methylation for the entire
pathway, we found that miR-200 hypermethylation and
ZEB1/ZEB2 upregulation were associated with down-
regulation in CDH1, CRB3 and LGL2 (Supplementary
Figure 2). The high level of expression of ZEB1 and the
converse minimal levels of E-cadherin in miR-200-
hypermethylated cancer cell lines, a characteristic
feature in the EMT phenotype, were conﬁrmed by
western blot (Supplementary Figure 2).
We also reconstituted miR-200 activity by cloning each
cluster (200ba429 and 200c141) followed by its stable
transfection in the CpG island-hypermethylated cancer
cell lines H157 and MDA-MB-231 (Supplementary
Figure 2). We observed that stable transfection of the
200ba429 or 200c141 pri-miRNA clusters in both miR-
200-hypermethylated cell lines caused the downregulation
of their target genes, ZEB1 and ZEB2 (Supplementary
Figure 2), and an increase in the expression of the
downstream cell-adherence and polarity genes, E-cadherin,
CRB3 and LGL2 (Supplementary Figure 2).
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OncogeneReconstitution of miR-200 activity inhibits cellular
migration, tumor growth and metastasis formation
Previous data indicate that miR-200 expression reduces
motility and invasiveness while its inhibition increases
migration capability (Burk et al., 2008; Gregory et al.,
2008; Korpal et al., 2008; Gibbons et al., 2009). We
sought to investigate these activities in the context of
miR-200 epigenetic silencing. We ﬁrst evaluated the
effects of the miR-200 transfection in the hypermethy-
lated cancer cell line RKO using the wound-healing assay.
We observed that, in both cell lines, stable transfection
of the clusters 200ba429, 200c141 or both together
Figure 1 CpG island hypermethylation-associated silencing of the miR-200 family in human cancer cell lines. (a) Schematic depiction
of miR-200ba429 and miR-200c141 genomic loci. CpG islands (blue boxes) and transcription start sites (arrows) are shown.
(b) Bisulﬁte genomic sequencing analysis of miR-200ba429 and miR-200c141 CpG islands in cancer cell lines. Six single clones are
represented for each cell line. Location of bisulﬁte genomic sequencing PCR primers (black arrows) and CpG dinucleotides (vertical
lines) are shown. Presence of unmethylated or methylated CpGs is indicated by white or black squares, respectively. (c) Expression of
mature miRNAs of the miR-200 family in cancer cell lines, evaluated by qRT–PCR. Data represent relative quantiﬁcation
(mean±s.d.). (d) Restored mature miR-200 expression upon treatment with DNA-demethylating agent 5-aza-20-deoxycytidine (aza)
in miR-200 CpG island methylated cell lines (Student’s t-test Po0.05 in all experiments).
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Oncogenepri-miRNAs caused a signiﬁcant reduction in the
migration rate (Fisher’s exact test Po0.01) (Figure 2a).
The inhibition of cell migration was not observed before
24h, and the reduced migration rate observed later was
not associated with diminished cell proliferation deter-
mined by the MTT assay (Supplementary Figure 3).
Next, we performed in vivo functional experiments in
nude mice. First, to test the tumorigenic capability we
Figure 2 Reconstitution of miR-200 levels inhibits cellular migration, tumor growth and metastasis formation. (a) Stable transfection
of pri-miR-200ba429, pri-miR-200c141 and both clusters (pri-miR-200ba429 and -200c141) in the CpG island-hypermethylated cancer
cell lines RKO caused decreased migration capability revealed by wound-healing assay. Accurate measures of the wounds were taken
at 0, 24, 48 and 72h to calculate the migration rate. Data are means±s.d. from two independent experiments (Fisher’s exact test
Po0.01 vs empty vector in all experiments). Illustrative examples of the time-coursed wound-healing assays are shown in the upper
panel. (b) Tumor development of xenograft mouse models was monitored during 45 days after subcutaneous injection of empty vector
or pri-miR-200c141 stably transfected RKO cells. Restoring of miR-200c141 in the hypermethylated RKO cells led to a signiﬁcant
reduction of tumor volume (Student’s t-test P¼0.02) and weight (Student’s t-test P¼0.04). Representative tumors are shown in the
upper panel. (c) Decreased metastatic potential by forced miR-200c141 expression in methylated RKO cells. The presence of
metastases was evaluated after 2 months of intrasplenic injection of pri-miR-200c141 or empty-vector RKO-transfected cells.
Illustrative examples are shown in the left panel. Metastases are indicated by arrows.
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Oncogeneestablished xenograft models by subcutaneous injection
of cancer cells transfected with the pri-miRNA 200c141
cluster, or the corresponding empty vector, into each
ﬂank of the mice. Notably, transfection of miR-200c141
in the miR-200-hypermethylated RKO cells signiﬁcantly
reduced their tumorigenicity as measured by tumor mass
(Student’s t-test P¼0.04) and volume (Student’s t-test
P¼0.02) (Figure 2b). We also tested the possible effect
of miR-200 reconstitution in hypermethylated cancer
cells upon metastatic potential. Following intrasplenic
injection of miR-200-hypermethylated RKO cells stably
transfected with the pri-miR-200c141 cluster, the devel-
opment of hepatic metastases was analyzed. We found
that, after 8 weeks, the mice injected with the miR-
200c141 reconstituted-RKO cells presented liver metas-
tases in only 25% (2/8) of cases, while the RKO-empty
vector-transfected cells developed metastases in 67%
(6/9) of the mice (Figure 2c).
Dynamic epigenetic silencing of the miRNA-200 family
during in vitro-induced EMT and MET
Once we had established how the CpG island hyper-
methylation-associated silencing of miR-200 enhanced
the tumorigenic features and re-expression of these
transcripts inhibited the malignant phenotype, we began
to study the dynamics of the process. In view of the
increasing evidences of the importance of EMT and
MET in the progression of the primary and metastatic
disease (Brabletz et al., 2001; Thiery, 2002; Chaffer
et al., 2006, 2007; Hugo et al., 2007; Yang and
Weinberg, 2008; Acloque et al., 2009; Thiery et al.,
2009; Kalluri and Weinberg, 2009; Polyak and Wein-
berg, 2009; Zeisberg and Neilson, 2009; Aokage et al.,
2010) and the critical roles of the miR-200 family in
these processes (Hurteau et al., 2006; Christoffersen
et al., 2007; Hurteau et al., 2007; Burk et al., 2008;
Gregory et al., 2008; Korpal et al., 2008; Park et al.,
2008), it is plausible that the establishment of the DNA
methylation patterns in the 50-CpG islands of the miR-
200 might be a reversible process that allows cellular
plasticity and adaptation to new microenvironments.
To explore this possibility, we ﬁrst used a well-known
model of induced EMT, the treatment with transform-
ing growth factor b (TGFb) of Madin–Darby canine
kidney cells (MDCK) (Moreno-Bueno et al., 2009).
TGFb is a potent inductor of EMT through several
pathways, including the Smad pathway (Zavadil and
Bottinger, 2005; Pardali and Moustakas, 2007; Xu et al.,
2009). This is a reversible process and the cells can
eventually undergo MET upon withdrawal of TGFb
from the culture medium (Figure 3a). Bisulﬁte genomic
sequencing of multiple clones of the 50-CpG islands of
the miR-200ba429 and miR-200c141 demonstrated that,
in agreement with the observed epithelial phenotype,
these CpG sites are unmethylated in untreated MDCK
cells (Figure 3b). The unmethylated CpG islands are
associated with strong expression of the miR-200
(Figure 3c). However, upon induction of EMT by
TGFb treatment, there is a progressive gain of CpG
methylation in the miR-200ba429 and miR-200c141
CpG islands (Figure 3b) in association with a reduced
expression of the miR-200 (Figure 3c). Most notably,
when these cells then underwent a change to a MET
phenotype after TGFb withdrawal from the medium
(Figure 3a), the previously methylated CpG islands
recovered the original unmethylated CpG status
(Figure 3b), and the expression of the miR-200 was
restored (Figure 3c). We also performed quantitative
chromatin immunoprecipitation studies for three his-
tone modiﬁcation marks in the miR-200ba429 and miR-
200c141 CpG islands in the EMT/MET MDCK model:
two marks of active transcription (H3K4 trimethylation
and H3K36 trimethylation) and one of silencing
(H3K27 trimethylation). We observed that the DNA
unmethylated CpG islands of the miR-200 loci were
enriched in active marks (H3K4 trimethylation and
H3K36 trimethylation) and depleted of the transcrip-
tional silencing H3K27 trimethylation mark (Supple-
mentary Figure 4). In contrast, the gain of CpG island
methylation of the miR-200ba429 and miR-200c141 loci
was associated with an increase in the silencing mark
(H3K27 trimethylation) and a depletion of the active
marks (H3K4 trimethylation and H3K36 trimethyla-
tion) (Supplementary Figure 4). MDCK cells that
underwent EMT upon TGFb use at the time points of
10, 20 and 30 days were also treated with 50-aza-20-
deoxycytidine during 72h. We observed that upon the
use of DNA-demethylating agent, the miR-200ba429
and miR-200c141 CpG islands underwent hypomethyla-
tion events associated with a restoration of the expres-
sion of the corresponding miRNA transcripts (Figure 3d
and Supplementary Figure 5). The epigenetic reactiva-
tion of the described miR-200 loci was associated
with the acquisition of epithelial features, such as the
downregulation of ZEB1 and the upregulation of
E-cadherin (Supplementary Figure 5).
The role of dynamic miR-200 epigenetic silencing in
the establishment of EMT and MET was conﬁrmed in
two additional experimental lines. First, the described
miR-200 hypermethylation-associated inactivation in
the TGFb-induced EMT was accompanied by increased
ZEB1 expression, loss of E-cadherin and the acquisition
of a spindle-like shape, a mesenchymal phenotype
marked by Vimentin (Supplementary Figure 6). Second,
the subsequent acquisition of a MET phenotype upon
TGFb depletion was not only characterized by the
hypomethylation and re-expression of the aforemen-
tioned miR-200ba429 and miR-200c141 clusters, but
also by a depletion of ZEB1 and Vimentin expression
and the enhancement of the E-cadherin signal (Supple-
mentary Figure 6). The ZEB1 and E-cadherin promoter
CpG islands were found unmethylated in all the
different stages of EMT and MET studied in MDCK
cells (Supplementary Figure 7).
Dynamic epigenetic silencing of the miRNA-200 family
during in vivo metastasis formation
The observation of the reversible miR-200 CpG island
methylation patterns in cell culture during EMT and
MET transitions, described above, prompted us to
consider whether these dynamic epigenetic changes also
took place in in vivo models of metastases where cancer
Dynamic epigenetic regulation of miR-200
V Davalos et al
2066
Oncogenecells also undergo important phenotypic changes. To
address this matter, we used two mouse models: a paired
human primary/metastasis breast cancer cell line ob-
tained from the animal system and the analyses of liver
metastases generated in nude mice by the intrasplenic
injection of a human colorectal cancer cell line.
In the ﬁrst case, we used an available model to analyze
the EMT process occurring in metastasis, the paired
breast cancer cell lines 468PT and 468LN (Vantyghem
et al., 2005). The 468PT cell line was generated by stable
transfection of the human breast adenocarcinoma cell
line MDA-MB-468 with the pEGFP-C2 expression
vector, whereas 468LN was derived from lung metas-
tases dissected from a nude mouse following orthotopic
injection with 468PT cells (Vantyghem et al., 2005).
In contrast to the epithelioid phenotype of the parental
468PT cell line, 468LN are spindle-shaped cells,
morphological changes associated with EMT. The
468LN cells produce extensive spontaneous lymph node
metastases following orthotopic injection in nude mice,
in contrast to the poorly metastatic MDA-MB-468
(Vantyghem et al., 2005). In agreement with the data
Figure 3 Dynamic epigenetic regulation of miR-200 expression during in vitro induced EMT and MET. (a) The epithelial MDCK
cells underwent morphological changes toward a mesenchymal phenotype (EMT) during TGFb treatment that was reverted after
TGFb withdrawal (mesenchymal to epithelial transition, MET). (b) Progressive gain of CpG methylation in both clusters of miR-200
family during TGFb-induced EMT, revealed by bisulﬁte genomic sequencing. The original unmethylated status was re-established in
cells undergoing MET after TGFb withdrawal. In all, 20 single clones were evaluated in each experimental condition. Presence of
unmethylated or methylated CpGs is indicated by white or black squares, respectively. (c) Decreased expression of mature miR-200
family members during TGFb treatment (Student’s t-test Po0.05), which was recovered after TGFb withdrawal, analyzed by qRT–
PCR. (d) Restored expression of miR-200 in TGFb-treated cells is achieved upon treatment with DNA-demethylating agent 5-aza-20-
deoxycytidine (aza), evaluated by qRT–PCR of mature miR-200 family members (Student’s t-test Po0.05).
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Oncogeneobtained from the MDCK model, we observed that
although miR-200ba429 and miR-200c141 loci both
featured unmethylated 50-CpG islands in the epithelial
breast cancer cell line 468PT (Figure 4a), associated with
a high level of expression of the transcripts (Figure 4b),
the spindle-shaped metastatic 468LN cells underwent a
dense CpG island hypermethylation for both miR-200
clusters (Figure 4a) that was linked to transcriptional
silencing (Figure 4b). The use of a DNA-demethylating
agent in the 468LN cell line was able to restore the
expression of the miR-200ba429 and miR-200c141
transcripts (Figure 4c). The CpG island hypermethyla-
tion-associated silencing of the miR-200 in the meta-
static 468LN was associated with the acquisition of an
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OncogeneEMT phenotype with upregulation of the ZEB1 and
Vimentin proteins and downregulation of E-cadherin
(Supplementary Figure 8), relative to the miR-200
unmethylated parental epithelial cell line 468PT. Upon
transfection of miR-200ba429, miR-200c141 or both
loci together, the exogenous re-expression of these miR-
200 loci transcripts reversed the phenotype of the
mesenchymal-like 468LN cells: they acquired an epithe-
lioid phenotype with ZEB and Vimentin downregulation
and upregulation of the ZEB target CRB3 (Supplemen-
tary Figure 9). These changes were not associated with
any change in the DNA methylation status of the
endogenous miR-200ba429 and miR-200c141 CpG
islands that stayed hypermethylated (Supplementary
Figure 9).
In the second approach, we generated a mouse model
of hepatic metastasis by intrasplenic injection of the
human colorectal cancer cell line SW620. We injected
2 10
6 cells into 15 animals and veriﬁed the occurrence
of metastasis in liver 8 weeks later. SW620 was able to
generate macroscopic liver metastasis after 2 months in
9 of the 15 (60%) mice (Figure 4d). The miR-200ba429
50-CpG island remained unmethylated in all cases
(Supplementary Figure 10). Strikingly, in two of the
mice carrying the hepatic metastases, the miR-200c141
epigenetic pattern was distinct from that observed in the
parental cell line: if the original SW620 had an
unmethylated CpG island (Figure 4e and Supplemen-
tary Figure 11) associated with expression of the
transcript (Figure 4f), the liver metastases of SW620
had experienced dense miR-200c141 CpG island
methylation (Figure 4e and Supplementary Figure 11)
and loss of expression (Figure 4f) in association with the
gain of EMT features such as ZEB1, ZEB2 and
Vimentin overexpression and E-cadherin depletion
(Figure 4g). These latter results in colorectal dissemina-
tion, together with the paired 468PT/468LN breast
cancer experiment described above, highlight the role of
epigenetic plasticity in miR-200 activities and later
tumor propagation.
Differential miR-200 CpG island methylation in epithelial
and stromal cells of human colonic mucosa
Having demonstrated that miR-200 CpG island methy-
lation-associated silencing was characteristic of the
mesenchymal phenotypes, while the unmethylated and
expressing status of the CpG island was linked to
epithelial features, we investigated whether these differ-
ent DNA methylation patterns were also observed in
human primary tissues. We took normal colon mucosa
as a model. Bisulﬁte genomic sequencing of multiple
clones (Figure 5a) and methylation-speciﬁc PCR ana-
lyses (Supplementary Figure 11) of the miR-200ba429
and miR-200c141 50-CpG islands in primary total
normal colorectal mucosa samples revealed a mixture
of hypermethylated and unmethylated alleles in all the
studied cases (n¼10). These results may reﬂect the
existence of a heterogeneous population within the
sample: methylated/silenced and unmethylated/expres-
sing. The stromal and epithelial components of the
normal colon mucosa were good candidates in each
respective category. Thus, we mechanically isolated the
Lieberku ¨ hn colorectal crypts (the epithelial component)
(Figure 5b) and the lamina propria-stromal cells (the
mesenchymal component), and proceeded with the
DNA methylation analyses. Normal epithelial cells from
the colorectal crypts had unmethylated 50-CpG islands
for both miR-200ba429 and miR-200c141 (Figure 5c)
and expressed the corresponding transcripts (Figure 5d),
whereas lamina propria cells were hypermethylated at
the miR-200 CpG islands (Figure 5c) and lacked
expression of these miRNAs (Figure 5d). Consistent
with the described observations, miR-200ba429 and
miR-200c141 unmethylated crypt cells had minimal
ZEB1 and ZEB2 expression, while the miR-200-hyper-
methylated stromal cells in the colon mucosa showed
upregulated ZEB1/ZEB2 transcripts (Figure 5e). Thus,
50-CpG island methylation of the miR-200 loci is an
important component in the compartmental distinction
between cell lineages in normal colon mucosa.
The next question to address was how the speciﬁc
identiﬁed miR-200 CpG island methylation pattern that
distinguishes the epithelia from the mesenchymal
component of the normal colon mucosa could be
disrupted in human colorectal tumorigenesis. Thus, we
used laser microbeam microdissection and pressure
catapulting to analyze the four tissue components found
in 25 colorectal cancer patients: normal epithelium (the
crypts) and stroma neighboring the colorectal tumor
and, within the malignant pathological mass, its tumor
Figure 4 Dynamic epigenetic silencing of the miRNA-200 family during in vivo metastasis formation. (a) CpG hypermethylation of
both miR-200 clusters in the lung metastasis-derived 468LN cell line, in contrast to unmethylated status in the parental 468PT
epithelial breast cancer cell line, analyzed by bisulﬁte genomic sequencing. In all, 20 single clones are represented for each cell line.
Presence of unmethylated or methylated CpGs is indicated by white or black squares, respectively. (b) Signiﬁcant reduction of miR-200
expression in metastatic 468LN cells (Student’s t-test Po0.01). Data represent relative quantiﬁcation of miRNAs, using the parental
468PT cell line as reference. (c) Restored expression of miR-200 in 468LN cells upon DNA-demethylating treatment with 5-aza-20-
deoxycytidine (aza), detected by qRT–PCR (Student’s t-test Po0.05). (d) CpG island hypermethylation of miR-200c141 cluster during
hepatic metastasis formation in mice. Spleen injection of 2 10
6 human colon cancer SW620 cells was able to generate hepatic
metastases in 9 out of 15 mice after 8 weeks. Illustrative examples of metastases are shown (white arrows). (e) miR-200c141 CpG island
methylation analysis of the hepatic metastases derived from SW620 shows hypermethylation of the cluster in two of them (HM3 and
HM4), in contrast to the unmethylated status of the original SW620 cell line (CL). Results were obtained by bisulﬁte genomic
sequencing analysis. Presence of unmethylated or methylated CpGs is indicated by white or black squares, respectively. (f) Signiﬁcant
decrease of pri-miR-200c141 in a CpG-hypermethylated hepatic metastasis (HM3) in comparison with the unmethylated metastases
and original SW620 cell line (Student’s t-test Po0.01). Data represent means±s.d. and were obtained by qRT–PCR. (g) Gain of
expression of ZEB1, ZEB2 and Vimentin, and repression of E-cadherin in a miR-200c141-methylated hepatic metastasis (HM3).
Human (hGAPDH) or mouse GAPDH (mGAPDH) were used as endogenous controls in semiquantitative RT–PCR. CL: original
SW620 cell line; mNL: mouse normal liver.
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Oncogeneepithelium (TE) and tumor stroma (Figure 6a). Bisulﬁte
genomic sequencing demonstrated that the miR-200-
hypermethylated 50-CpG islands of the stroma of
normal colorectal mucosa continued to be densely
methylated in the stroma within colorectal tumors
(Figure 6b) with minimal miRNA expression
(Figure 6c). However, the 50-CpG island of miR-
200c141 underwent a hypermethylation event in the
tumor epithelial cells relative to the unmethylated status
of epithelium from the normal mucosa in 40% (10/25) of
colorectal cancer patients (Figure 6b). miR-200c141
CpG island hypermethylation in the TE was associated
with the transcriptional silencing of the transcript
(Figure 6c). Following immunostaining for the epithelial
marker E-cadherin in the 25 studied TE samples, among
the cases that showed minimal expression of E-cadherin,
miR-200c-141 CpG island hypermethylation was ob-
served in six of eight (75%) cases (Supplementary Figure
12). None of the 25 analyzed TE samples showed
E-cadherin CpG island hypermethylation (Supplemen-
tary Figure 12). miR-200c-141 CpG island hypermethy-
lation was not observed in pre-neoplastic colorectal
lesions (ﬁve microdissected adenomas) (Supplementary
Figure 13). It is worth noting that the miR-200ba429
CpG island did not undergo dense methylation in the
TE in the studied samples (Supplementary Figure 14),
which suggests that different tissue and cancer-type
activities might exist within the miR-200 family.
Discussion
The dynamic nature of the contribution of the DNA
methylation mark to the ‘survival skills’ of cancer cells
within the human body host is emerging as a critical tool
for accomplishing this goal. Although many external
and microenvironmental agents could be involved in
shifting DNA methylation patterns, it is interesting
that TGFb seems to have a role in one case, that of
the MDCK system. TGFb induced EMT, and its
withdrawal caused MET, linked with the corresponding
Figure 5 Differential miR-200 CpG island methylation in epithelial and stromal cells of normal human colonic mucosa. (a) miR-
200ba429 and miR-200c141 50-CpG island methylation analyses by bisulﬁte genomic sequencing in primary total normal colon mucosa
samples demonstrated a mixture of unmethylated and methylated alleles. Illustrative examples are shown. (b) Epithelial and stromal
components of human colonic mucosa were mechanically isolated. Illustrative microscope photographs in conventional bright-ﬁeld
illumination (left panel) or under phase contrast (right panel) of epithelial colonic crypts are shown. (c) Lack of DNA methylation in
miR-200 CpG islands in epithelial component (colonic crypts), but hypermethylation in the surrounded lamina propria-stromal cells
derived from normal colonic mucosa samples (NM), studied by bisulﬁte genomic sequencing. Illustrative examples are shown. (d) High
miR-200 expression levels in unmethylated colonic crypts and loss of expression in methylated lamina propria cells, evaluated by
qRT–PCR of primary miRNAs (Student’s t-test Po0.01). (e) Inhibition of ZEB1 and ZEB2 mRNA expression in miR-200
unmethylated crypts (c), in contrast to high expression in miR-200-methylated lamina propria (LP) cells. GAPDH was used as
endogenous control in semiquantitative RT–PCRs.
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Oncogene50-CpG island methylation changes at miR-200ba429
and miR-200c141. Interestingly, an analogous de novo
DNA methylation event in response to TGFb has
recently been reported as being an inactivation mechan-
ism of b-4 integrin in NMuMG mouse mammary gland
epithelial cells undergoing EMT (Yang et al., 2009).
Likewise, acquisition of CpG methylation in several
gene promoters, such as Twist, has been described upon
serum-induced EMT in immortalized human mammary
epithelial-expressing oncogenic ras cells (Dumont et al.,
2008). Thus, local microenvironment and signals from
tumor-associated stroma, including TGFb that appear
to be important for the induction and functional
activation of EMT-related pathways (Zavadil and
Bottinger, 2005; Pardali and Moustakas, 2007; Xu
et al., 2009), might also mediate these effects through
the action of epigenetic switches such as miR-200 50-
CpG island methylation events. The ﬁnding of possible
triggers and controllers of the observed miR-200 loci
DNA methylation dynamics in EMT would be extre-
mely interesting. TGFb has been involved in the
establishment of DNA methylation patterns in cancer
cells (reviewed by Chou et al., 2010) and in the activity
of two epigenetic proteins, MTA1 (Pakala et al., 2011)
and HDAC6 (Shan et al., 2008), in EMT. In addition,
other histone modiﬁers, such as LSD1 (Lin et al., 2010),
CREB-binding protein (Abell et al., 2011) and SIRT1
(Eades et al., 2011), also contribute to EMT.
Our study provides further clues about the paradox-
ical role of the miR-200 family during tumor progres-
sion and metastasis. During early tumor development,
from the 50-unmethylated miR-200 CpG islands the
transcripts are produced and initially ‘secure’ the
epithelial phenotype. However, the tumors progress
and gain CpG promoter hypermethylation with a lack
of miR-200 expression that promotes metastasis. In this
regard, lower levels of miR-200c have been associated
with a higher frequency of lymph node metastases in
non-small cell lung cancer patients (Ceppi et al., 2010),
and miR-200 downregulation is observed in metastatic
lymph nodes (Baffa et al., 2009). However, once the
micrometastases have been established, CpG island
demethylation and gain of miR-200 expression could
act as a macrometastasis promoter at the secondary
Figure 6 CpG island hypermethylation-associated silencing of miR-200c141 in human colorectal cancer. (a) Isolation of epithelial and
stromal cells from normal and tumor colonic mucosa using laser microbeam microdissection and pressure catapulting. (b) Aberrant
miR-200c141 CpG island hypermethylation in tumor epithelial cells (TE) in comparison with corresponding unmethylated normal
epithelial crypts (NE), evaluated by bisulﬁte genomic sequencing. Both normal stroma (NS) and tumor stroma (TS) samples shown
dense methylation. (c) Decreased expression of mature miR-200c and miR-141 in hypermethylated TE samples in contrast to high
expression in paired normal epithelium samples. Both NS and TS samples showed low levels of miR-200c141. Data represent
mean±s.d., obtained by qRT–PCR (Student’s t-test Po0.05).
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multistep metastasis process are limited. Studies of
isogenic cancer cell lines have shown that sub-lines
overexpressing miR-200 (Dykxhoorn et al., 2009) or
with more epithelial phenotypes (Chaffer et al., 2006)
more efﬁciently produced local colonization growth and
macrometastases than those with low miR-200 levels or
mesenchymal-like phenotypes. Thus, if metastatic tu-
mors tend to recapitulate the traits of the primary tumor
from which they arose, including epithelial features
favorable to tumor growth in the secondary organ, CpG
hypermethylation of the miR-200 family could be a
transitional state. Under such circumstances, epigenetic
silencing of these master regulators of the epithelial
phenotype could initially facilitate the dissemination
of cancer cells, although restoring unmethylated
miR-200 CpG island status and undergoing MET could
be advantageous once the cells have reached the
secondary site.
Many aspects remain to be investigated in future
research. The ﬁrst is the recognition of the presence of
different miR-200 50-CpG island DNA methylation
patterns according to the epithelial or mesenchymal
origin of the cell type. This ﬁnding is supported by the
distinct miR-200c141 methylation proﬁle observed in
mammary epithelial cells and isogenic ﬁbroblasts (Vrba
et al., 2010). In addition, a miR-200 downregulation has
been reported in the mesenchymal component of
endometrial carcinosarcomas in comparison with the
epithelial part, conﬁrming the role of miR-200 in EMT
in human tumors (Castilla et al., 2011). These results
indicate the need for careful microdissection experi-
ments if we want to exploit the potential of miR-200
CpG island hypermethylation as a biomarker of tumor
behavior for future clinical purposes. Second, our results
might provide a molecular base for new uses of
pharmacological compounds with DNA-demethylating
activity in the treatment of cancer patients (Mack,
2006; Issa, 2007; Esteller, 2008; Kaiser, 2010). Drug-
induced miR-200 CpG island demethylation, which
restores the expression of these transcripts, might inhibit
tumor progression and micrometastasis formation
mediated by EMT, as suggested by our in vitro and
in vivo results. This area warrants further pre-clinical
research, because of the potential beneﬁts it offers for
the treatment of cancer patients with metastatic disease,
where extremely few therapeutic options are currently
available.
Materials and methods
Cell lines and DNA methylation analysis
Cell lines and culture conditions are detailed in Supplementary
Methods. For epigenetic drug treatments, cells were treated
with 2mM 5-aza-20-deoxycytidine (Sigma, St Louis, MO, USA)
for 72h. For TGFb treatments, recombinant human TGFb
(R&D systems, Minneapolis, MN, USA) was added to the
culture medium at a ﬁnal concentration of 5ng/ml. CpG
islands were identiﬁed in silico using Methyl Primer Express
v1.0 software (Applied Biosystems, Carlsbad, CA, USA).
DNA methylation status was established by bisulﬁte genomic
sequencing of multiple clones and methylation-speciﬁc PCR.
Primers are listed in Supplementary Table 1.
RNA extraction and real-time qRT–PCR
Total RNA was extracted using Trizol (Invitrogen, San Diego,
CA, USA) and DNase-treated with Turbo DNA-free (Am-
bion, Austin, TX, USA). mRNA expression was analyzed
using SYBR Green (Applied Biosystems). For miRNA
quantiﬁcation, TaqMan Pri-miRNA or MicroRNA Assays
(Applied Biosystems) (Chen et al., 2005) were used according
to the manufacture’s protocol. Further information is de-
scribed in Supplementary Methods. Primers and TaqMan
assays are listed in Supplementary Table 1.
Protein extraction, western blot and immunoﬂuorescence
Cell pellets were lysed in RIPA buffer containing complete
protease inhibitor cocktail (Roche, Mannheim, Germany).
Proteins were quantiﬁed with DC Protein Assay (Bio-Rad,
Hercules, CA, USA) and 50mg of whole-cell lysates were
separated by SDS–PAGE. Blots were probed using anti-ZEB1
antibody (sc-10572, Santa Cruz Biotechnology, Santa Cruz,
CA, USA), anti-Vimentin (CBL-202, Chemicon-Millipore,
Billerica, MA, USA) or anti-E-cadherin (ab-1416, Abcam,
Cambridge, UK). Proteins were detected using horseradish
peroxidase-conjugated secondary antibodies. For immuno-
ﬂuorescence, cells were cultured directly on coverslips and
double immunostainings were performed as detailed in
Supplementary Methods.
miR-200 cloning and stable transfection
The genomic regions surrounding the pri-miRNA sequences of
miR-200 family members were ampliﬁed using primers listed in
Supplementary Table 1. Products were directionally cloned in
pSilencer 4.1-CMV puro (Ambion). Cells seeded in six-well
plates were transfected using Lipofectamine 2000 (Invitrogen),
according to the manufacturer’s instructions.
Wound-healing assay
Control and miR-200 stably transfected cells were grown to
conﬂuence, and a wound was made through the monolayer
using a p1000 tip. Accurate measures of the wounds were
taken during the time course to calculate the migration rate
according to the equation: percentage wound healing¼
((wound length at 0h) (wound length at 24, 48 or 72h))/
(wound length at 0h) 100. Two independent experiments
were performed.
Mouse xenograft and metastasis models
Five-week-old male athymic nu/nu mice (Charles River,
Wilmington, MA, USA), housed under speciﬁc pathogen-free
conditions, were used in this study. For xenografts, a total of
3.5 10
6 cells were subcutaneously injected in each ﬂank of the
mouse. The right ﬂank was used for RKO control cells (empty
vector) and the left for the miR-200c141 stably transfected
RKO cells. Tumor development was monitored every 5 days
and the tumor width (W) and length (L) were measured.
Tumor volume was estimated according to the formula V¼p/
6 L W
2. Mice were killed 45 days after injection, and
tumors were then excised and weighed. For the experimental
metastasis assay, mice were anesthetized, the spleens were
exposed through a cut on the left ﬂank and 2 10
6 control
(empty vector) or miR-200c141 stably transfected RKO cells
were injected into the middle of spleen. In order to minimize
local tumor growth, the spleens were resected 48h after
injection. Hepatic metastasis were examined 8 weeks later,
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Oncogeneanalyzed macroscopically and by H&E tissue staining. In all,
10 animals were tested for each experimental condition. All
experiments with mice were approved by the IDIBELL Animal
Care and Use Committee.
Colonic crypt isolation from fresh tissue
Colonic tissues were obtained from surgical resection of
colorectal cancer patients at the Bellvitge Hospital, Barcelona,
Spain. Written informed consents were obtained from all
patients. Colonic crypts were isolated by a previously
described method (Fujimoto et al., 2002). Lamina propria
and crypt samples were snap-frozen in liquid nitrogen and
stored at  801C before DNA and RNA extraction.
Laser microdissection from parafﬁn-embedded and frozen tissues
Tissues were provided by the Department of Pathology,
Hospital Sa ˜ o Joa ˜ o, Porto, Portugal. All patients gave written
consent and the hospital Ethics Committee approved the
study. Laser microbeam microdissection and pressure cata-
pulting process is detailed in Supplementary Methods.
A minimum of 1,500 cell equivalents were isolated. DNA
and RNA were extracted using a RecoverAll Total Nucleic
Acid Isolation Kit for FFPE Tissues (Ambion).
Statistical analyses
Experiments were performed in triplicate and Fisher’s exact
test or Student’s two-tailed t-test were used to identify
statistical signiﬁcance of differences between group means.
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